Orgenesis Inc (ORGS) USD0.0001

Sell:$1.40Buy:$1.40$0.09 (6.87%)

Prices delayed by at least 15 minutes
Sell:$1.40
Buy:$1.40
Change:$0.09 (6.87%)
Prices delayed by at least 15 minutes
Sell:$1.40
Buy:$1.40
Change:$0.09 (6.87%)
Prices delayed by at least 15 minutes

Company Information

About this company

Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.

Key people

Vered Caplan
Chairperson of the Board of Directors, Chief Executive Officer
Victor Miller
Chief Financial Officer, Treasurer, Secretary
Yaron Adler
Independent Director
Santhosh Nagaraj
Independent Director
Ashish Nanda
Independent Director
Adam Pelavin
Independent Director
Itzhak Vider
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Medical Equipment & Supplies
  • ISIN
    US68619K3032
  • Market cap
    $7.18m
  • Employees
    146
  • Shares in issue
    5.23m
  • Exchange
    Over The Counter
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.